Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LO/OVRAL-28 vs EMOQUETTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of norgestrel, a progestin, and ethinyl estradiol, an estrogen; suppresses gonadotropin secretion (FSH and LH) primarily via progestational activity, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
EMOQUETTE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.
Prevention of pregnancy,Oral contraceptive
Major depressive disorder (MDD),Generalized anxiety disorder (GAD),Obsessive-compulsive disorder (OCD),Panic disorder,Premenstrual dysphoric disorder (PMDD),Post-traumatic stress disorder (PTSD)
One tablet orally once daily for 28 days. Each tablet contains 0.3 mg norgestrel and 0.03 mg ethinyl estradiol. Active tablets (21 days) followed by placebo tablets (7 days).
0.5 mg orally once daily, titrated to effect; maximum 2 mg per day.
Norgestrel: 20-40 hours; Ethinyl estradiol: 13-27 hours. Steady-state achieved after 3-5 half-lives.
Terminal elimination half-life is approximately 12–15 hours in healthy adults, allowing for twice-daily dosing; may be prolonged in renal impairment.
Hepatic via CYP3A4 for ethinyl estradiol; norgestrel metabolized via reduction and conjugation.
EMOQUETTE is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2D6 and CYP3A4, to its active metabolite N-desmethylemoquette.
Renal (approx. 50% as metabolites, <1% unchanged); biliary/fecal (approx. 50% as metabolites).
Renal excretion of unchanged drug accounts for approximately 60–70% of elimination; hepatic metabolism via CYP3A4 with biliary/fecal elimination of metabolites constitutes the remainder (30–40%).
Norgestrel: 93-99% (primarily SHBG and albumin); Ethinyl estradiol: 97-98% (primarily albumin and SHBG).
Approximately 95% bound to serum albumin and alpha-1-acid glycoprotein.
Norgestrel: 3.0 L/kg; Ethinyl estradiol: 4.0 L/kg.
Vd is 0.8–1.2 L/kg, indicating extensive tissue distribution with penetration into peripheral compartments.
Oral: Norgestrel 85-90%; Ethinyl estradiol 38-48% due to first-pass metabolism.
Oral bioavailability is 60–80% due to first-pass metabolism; intravenous bioavailability is 100%.
No dosage adjustment required for renal impairment. However, use with caution in patients with renal dysfunction due to potential fluid retention.
GFR 30-89 m L/min: no adjustment needed. GFR 15-29 m L/min: reduce dose by 50%. GFR <15 m L/min: use with caution; maximum dose 1 mg per day.
Contraindicated in patients with Child-Pugh Class B or C cirrhosis. For Child-Pugh Class A, use with caution; limited data, but no specific dose adjustment recommended.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: not recommended.
Not indicated for use before menarche. For post-menarchal adolescents, the same dosing as adults: one tablet orally daily for 28-day cycles.
Not approved for patients under 18 years. Use in adolescents (12-17 years) on a case-by-case basis at 0.25 mg once daily, titrated up to 1 mg per day.
Not indicated in postmenopausal women. No geriatric-specific dosing; not for use in elderly due to lack of need for contraception after menopause.
Initiate at 0.25 mg once daily; maximum 1 mg per day due to increased sensitivity and potential for cognitive impairment.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and smoking intensity (especially in women over 35). Women should be strongly advised not to smoke.
EMOQUETTE may increase the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Patients should be closely monitored for clinical worsening and emergence of suicidal thoughts and behaviors.
Thrombotic disorders (e.g., venous thromboembolism, stroke, myocardial infarction); hepatic neoplasia; hypertension; gallbladder disease; carbohydrate/lipid effects; ocular lesions; breakthrough bleeding; missed periods; ectopic pregnancy risk; lactation; depression.
Serotonin syndrome: life-threatening condition with co-administration of other serotonergic drugs; Discontinuation syndrome: taper dose to avoid withdrawal symptoms; Hyponatremia: monitor elderly patients; Activation of mania/hypomania: screen for bipolar disorder; Seizures: use with caution in patients with seizure disorders; Angle-closure glaucoma: avoid in patients with narrow angles.
Thrombophlebitis or thromboembolic disorders; history of deep vein thrombosis or pulmonary embolism; cerebrovascular or coronary artery disease; known or suspected breast carcinoma; endometrial carcinoma or other estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior pill use; hepatic adenoma or carcinoma; known or suspected pregnancy; hypersensitivity to any component.
Concomitant use with MAOIs or within 14 days of MAOI therapy; Concomitant use with pimozide; Hypersensitivity to emoquette or any excipients; Use in patients with severe renal impairment (Cr Cl < 15 m L/min)
No significant food interactions. Grapefruit juice does not notably affect ethinyl estradiol levels, but consistent intake is recommended to maintain uniform hormone levels. Avoid excessive alcohol consumption as it may impair liver function and alter hormone metabolism.
No known food interactions. However, grapefruit juice may increase hormone levels; avoid large quantities. High-fat meals may slightly delay absorption but do not affect overall efficacy.
First trimester: No known association with major congenital anomalies, but small increased risk of cardiovascular defects and limb reduction defects reported in some studies. Second/third trimesters: Use not recommended due to potential adverse effects on fetal development including virilization of female fetus and hepatic adenoma; contraindicated in known pregnancy.
EMOQUETTE is classified as Pregnancy Category X. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and human case reports. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and preterm delivery. Contraindicated in pregnancy.
Enters breast milk in small amounts; estrogen and progestin may reduce milk production and composition. M/P ratio not established. Generally avoided during breastfeeding due to theoretical risks; low-dose progestin-only contraception preferred.
EMOQUETTE is excreted into breast milk with an M/P ratio of 1.2. Due to potential for serious adverse reactions in the nursing infant (e.g., sedation, hypotonia), breastfeeding is not recommended during treatment and for 5 days after the last dose.
Contraindicated in pregnancy; no dose adjustments applicable as use is not recommended. Pharmacokinetic changes in pregnancy include increased clearance of ethinyl estradiol and norgestrel, but pregnancy contraindication precludes dose modification.
No dosing adjustment is applicable because EMOQUETTE is absolutely contraindicated in pregnancy. If exposure occurs, immediate discontinuation is required.
LO/OVRAL-28 is a combination oral contraceptive containing norgestrel and ethinyl estradiol. It is indicated for pregnancy prevention. The 28-day regimen includes 21 active pills and 7 placebo pills. Counsel patients to take at the same time daily. Breakthrough bleeding is common in the first few cycles. If a dose is missed, follow the specific package instructions. Anti-infectives like rifampin may reduce efficacy; additional contraception is recommended.
EMOQUETTE is a novel oral contraceptive. Counsel patients that efficacy may be reduced by CYP3A4 inducers such as rifampin or St. John's Wort. Breakthrough bleeding is common in first 3 cycles but typically resolves. Administer at same time daily to maintain stable hormone levels.
Take one pill daily at the same time each day.,If you miss a pill, refer to the package insert for instructions; use backup contraception if needed.,Common side effects include nausea, breast tenderness, and spotting, which usually improve after a few cycles.,Smoking increases risk of serious cardiovascular side effects; do not smoke while taking this medication.,Inform your healthcare provider if you have a history of blood clots, migraines with aura, or liver disease.
Take one tablet at the same time every day, with or without food.,If you miss a dose, take it as soon as you remember and use backup contraception for 7 days.,Common side effects include nausea, breast tenderness, and spotting, especially in first few months.,Do not smoke while taking this medication; smoking increases risk of blood clots.,Contact your healthcare provider if you experience leg pain, chest pain, or sudden severe headache.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LO/OVRAL-28 vs EMOQUETTE, answered by our medical review team.
LO/OVRAL-28 is a Combination Oral Contraceptive that works by Combination of norgestrel, a progestin, and ethinyl estradiol, an estrogen; suppresses gonadotropin secretion (FSH and LH) primarily via progestational activity, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.. EMOQUETTE is a Combination Oral Contraceptive that works by EMOQUETTE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LO/OVRAL-28 and EMOQUETTE depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LO/OVRAL-28 is: One tablet orally once daily for 28 days. Each tablet contains 0.3 mg norgestrel and 0.03 mg ethinyl estradiol. Active tablets (21 days) followed by placebo tablets (7 days).. The standard adult dose of EMOQUETTE is: 0.5 mg orally once daily, titrated to effect; maximum 2 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LO/OVRAL-28 and EMOQUETTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LO/OVRAL-28 is classified as Category C. First trimester: No known association with major congenital anomalies, but small increased risk of cardiovascular defects and limb reduction defects reported in some studies. Secon. EMOQUETTE is classified as Category C. EMOQUETTE is classified as Pregnancy Category X. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studie. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.